After months of negotiations, we are delighted to announce that Enantis has entered into a global license agreement with one of the top providers of life science solutions with our innovative FGF2-STAB® molecule and its use in research and cell therapy market.
“Having a licensing deal with a company from Fortune magazine’s yearly list of 500 largest US companies is a significant milestone for us,” says Roman Badik, CEO of Enantis.
Under the terms of agreement, Enantis along with Masaryk University have granted worldwide royalty-bearing license to manufacture FGF2-STAB® and develop new products containing this patented molecule. More details including the name of the licensee cannot be disclosed as per the terms of the license.